Replimune Group (REPL)
(Delayed Data from NSDQ)
$3.23 USD
-0.24 (-6.79%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.25 +0.03 (0.78%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Replimune Group, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
REPL 3.23 -0.24(-6.79%)
Will REPL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for REPL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REPL
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
REPL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for REPL
Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating
Narrow Range Bar appears for REPL after 6.79% move
Replimune (REPL) Faces Downgrade Amid Regulatory Uncertainty
Replimune cut to Underweight at J.P. Morgan on further headline risk
Intel downgraded, Tesla upgraded: Wall Street’s top analyst calls